PharmaShots | Incisive News in 3 Shots

Subscribe Now

Regardless of

Merck Receives the US FDA's Priority Review for Keytruda's (pembrolizumab) sBLA Based on Biomarker Regardless of Tumor Type

Merck Receives the US FDA's Priority Review for Keytruda's (pembrolizumab) sBLA Based on Biomarker Regardless of Tumor Type

April 7, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us